

Obefazimod data to be presented:

Presentation Title	Session	Presenter	Presentation/ Session Number	Session Hall	Date and Time (CEST)
<i>EFFICACY AND SAFETY OF OBEFAZIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM TWO, PHASE 3, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 8-WEEK INDUCTION TRIALS (ABTECT-1 &amp; 2)</i>	Late-breaking trials in IBD	Bruce Sands, MD	LB /01	<i>Room Helsinki</i>	<i>Sunday, October 5, 2025</i>  <i>5:00 to 5:12pm CEST</i>
<i>EFFICACY OF OBEFAZIMOD IN ABTECT PHASE 3 INDUCTION TRIALS: RESULTS OF 8-WEEK THERAPY IN SUBSETS OF PATIENTS WITH AND WITHOUT PRIOR INADEQUATE RESPONSE TO ADVANCED THERAPIES</i>	Hot off the press: IBD Treatment	Silvio Danese, MD	LB / 06	<i>Room Helsinki</i>	<i>Monday, October 6, 2025</i>  <i>10:00am to 10:12am CEST</i>